KIT and leukemia: Besides, in vivo disease reconstitution assay indicated that the recipient mice which received GFP+c‐Kit+ cells sorted from MS023‐treated primary CML mice had much lower leukemia burden (GFP+ cells; Figure S7Q, Supporting Information) and prolonged survival (median survival: Vehicle vs MS023 was 21 days vs not reached after monitoring for 60 days; Figure S7R, Supporting Information).